NCT05842486View on ClinicalTrials.gov

Hematological Response in Patients With Paroxysmal Nocturnal Hemoglobinuria Treated With Anti-C5 Antibody: an External Control Arm Study for Iptacopan Use in Anti-C5 naïve Patients

CompletedOBSERVATIONAL
Enrollment

92

Participants

Timeline

Start Date

January 18, 2023

Primary Completion Date

March 1, 2023

Study Completion Date

March 1, 2023

Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
OTHER

Anti-C5 antibody treatment

Anti-C5 antibody treatment (i.e., eculizumab and ravulizumab)

Trial Locations (1)

Unknown

AP-HP Hôpital Saint Louis, Paris

All Listed Sponsors
collaborator

Leeds Cancer Centre at St. James's University Hospital

OTHER

lead

Assistance Publique - Hôpitaux de Paris

OTHER